HUP0400350A3 - Novel cyano-substituted dihydropyrimidine compounds, process for producing them, their use and pharmaceutical compositions containing them - Google Patents

Novel cyano-substituted dihydropyrimidine compounds, process for producing them, their use and pharmaceutical compositions containing them

Info

Publication number
HUP0400350A3
HUP0400350A3 HU0400350A HUP0400350A HUP0400350A3 HU P0400350 A3 HUP0400350 A3 HU P0400350A3 HU 0400350 A HU0400350 A HU 0400350A HU P0400350 A HUP0400350 A HU P0400350A HU P0400350 A3 HUP0400350 A3 HU P0400350A3
Authority
HU
Hungary
Prior art keywords
producing
pharmaceutical compositions
compositions containing
dihydropyrimidine compounds
substituted dihydropyrimidine
Prior art date
Application number
HU0400350A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HUP0400350A2 publication Critical patent/HUP0400350A2/hu
Publication of HUP0400350A3 publication Critical patent/HUP0400350A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0400350A 2001-03-29 2002-03-26 Novel cyano-substituted dihydropyrimidine compounds, process for producing them, their use and pharmaceutical compositions containing them HUP0400350A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27995601P 2001-03-29 2001-03-29
PCT/US2002/009497 WO2002079149A2 (en) 2001-03-29 2002-03-26 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Publications (2)

Publication Number Publication Date
HUP0400350A2 HUP0400350A2 (hu) 2005-01-28
HUP0400350A3 true HUP0400350A3 (en) 2005-06-28

Family

ID=23071059

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400350A HUP0400350A3 (en) 2001-03-29 2002-03-26 Novel cyano-substituted dihydropyrimidine compounds, process for producing them, their use and pharmaceutical compositions containing them

Country Status (26)

Country Link
US (1) US6809102B2 (hu)
EP (1) EP1373221A4 (hu)
JP (1) JP2005504725A (hu)
KR (1) KR20030086327A (hu)
CN (1) CN1507435A (hu)
AR (1) AR034585A1 (hu)
BG (1) BG108180A (hu)
BR (1) BR0208405A (hu)
CA (1) CA2442482A1 (hu)
CZ (1) CZ20032645A3 (hu)
EE (1) EE200300474A (hu)
HR (1) HRP20030875A2 (hu)
HU (1) HUP0400350A3 (hu)
IL (1) IL157441A0 (hu)
IS (1) IS6967A (hu)
MX (1) MXPA03008634A (hu)
NO (1) NO20034300L (hu)
PE (1) PE20021013A1 (hu)
PL (1) PL373759A1 (hu)
RU (1) RU2003130961A (hu)
SK (1) SK11062003A3 (hu)
TW (1) TWI228416B (hu)
UY (1) UY27232A1 (hu)
WO (1) WO2002079149A2 (hu)
YU (1) YU75803A (hu)
ZA (2) ZA200306648B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900214B2 (en) * 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
EP1454903B9 (en) * 2001-12-11 2011-10-05 Kyowa Hakko Kirin Co., Ltd. Thiadiazoline derivatives for treating cancer
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
MXPA05009577A (es) * 2003-03-07 2005-12-12 Astrazeneca Ab Heterociclos fundidos novedosos y sus usos.
ES2377498T3 (es) * 2003-04-18 2012-03-28 Kyowa Hakko Kirin Co., Ltd. Inhibidor de quinesina en etapa M
KR20060014071A (ko) * 2003-06-10 2006-02-14 교와 핫꼬 고교 가부시끼가이샤 티아디아졸린 유도체
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
WO2005037799A1 (en) * 2003-10-16 2005-04-28 Cytokinetics, Inc. Compounds, compositions, and methods
KR20070044458A (ko) * 2004-07-22 2007-04-27 아스트라제네카 아베 암의 예방 및 치료에 유용한 융합 피리미돈
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
CA2575188A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
EP1870404A4 (en) * 2005-03-22 2010-07-14 Kyowa Hakko Kirin Co Ltd MEANS FOR THE TREATMENT OF A HEMATOPOIETIC TUMOR
KR20070113300A (ko) * 2005-03-22 2007-11-28 교와 핫꼬 고교 가부시끼가이샤 고형종양 치료제
EP1908755A4 (en) * 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd THERAPEUTIC AGENT AGAINST RESTENOSIS
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
CN110464722B (zh) * 2019-06-06 2023-05-23 暨南大学 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211198B1 (en) 1993-04-05 2001-04-03 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
EE9700209A (et) 1994-11-16 1998-04-15 Synaptic Pharmaceutical Corporation Dihüdropürimidiinid ja nende kasutamine
WO1997017969A1 (en) 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
JP2000506904A (ja) 1996-05-16 2000-06-06 シナプティック・ファーマスーティカル・コーポレーション ジヒドロピリミジン類およびその使用
US6080760A (en) 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
CA2294349A1 (en) 1997-06-18 1998-12-23 Michael A. Patane Alpha 1aadrenergic receptor antagonists
WO1999025345A1 (en) 1997-11-14 1999-05-27 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
WO1999050440A2 (en) 1998-04-01 1999-10-07 Yale University Method to identify modulators of survivin - tubulin interaction
US6300084B1 (en) 1998-10-08 2001-10-09 The Regents Of The University Of California Anti-mitotic agent screening process
AUPQ171999A0 (en) 1999-07-20 1999-08-12 University Of Sydney, The Neurotropic virus transport
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
ES2263501T3 (es) 1999-10-27 2006-12-16 Cytokinetics, Inc. Procedimiento y composiciones que utilizan quinazolinonas.
US6284480B1 (en) 2000-04-03 2001-09-04 Cytokinetics, Inc. Antifungal assay
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Also Published As

Publication number Publication date
CA2442482A1 (en) 2002-10-10
EP1373221A4 (en) 2004-09-29
HRP20030875A2 (en) 2004-08-31
MXPA03008634A (es) 2003-12-08
KR20030086327A (ko) 2003-11-07
IS6967A (is) 2003-09-24
EP1373221A2 (en) 2004-01-02
ZA200307320B (en) 2004-12-20
YU75803A (sh) 2006-05-25
BG108180A (en) 2004-09-30
US20030008888A1 (en) 2003-01-09
UY27232A1 (es) 2002-11-29
HUP0400350A2 (hu) 2005-01-28
SK11062003A3 (sk) 2004-08-03
IL157441A0 (en) 2004-03-28
CN1507435A (zh) 2004-06-23
NO20034300L (no) 2003-11-07
BR0208405A (pt) 2004-03-30
TWI228416B (en) 2005-03-01
PE20021013A1 (es) 2002-11-10
AR034585A1 (es) 2004-03-03
EE200300474A (et) 2003-12-15
US6809102B2 (en) 2004-10-26
CZ20032645A3 (cs) 2004-06-16
JP2005504725A (ja) 2005-02-17
ZA200306648B (en) 2004-11-26
NO20034300D0 (no) 2003-09-26
WO2002079149A3 (en) 2003-02-27
WO2002079149A2 (en) 2002-10-10
RU2003130961A (ru) 2005-04-10
PL373759A1 (en) 2005-09-05

Similar Documents

Publication Publication Date Title
HUP0402063A3 (en) Indole-2-carboxamides process for producing them, pharmaceutical compositions containing them and use thereof
HUP0402264A3 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof
HUP0402225A3 (en) Macrolide-compounds, process for their preparation and pharmaceutical compositions containing them
HUP0203766A3 (en) 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof and pharmaceutical compositions containing them
HUP0402588A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP0401241A3 (en) Novel cyclohexyl sulphones, process for their preparation and pharmaceutical compositions containing them
HUP0303458A3 (en) 6-substituted pyrido-pyrimidines, process for their preparation and pharmaceutical compositions containing them
HUP0301459A2 (en) Chemical compounds process for producing them and pharmaceutical compositions containing them
HUP0401301A3 (en) Pyrrolo pyrimidines, process for their preparation, their use and pharmaceutical compositions containing them
HUP0301187A3 (en) Novel benzyl-piperidine-derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0301069A3 (en) Novel biarylcarboxamides, process for their preparation, pharmaceutical compositions containing them and their use
HUP0401619A3 (en) Phenethanolamine derivatives, process for their preparation and pharmaceutical composition containing them
HUP0301842A3 (en) Lactam compound, pharmaceutical composition containing it and use of it for producing pharmaceutical composition
HUP0400350A3 (en) Novel cyano-substituted dihydropyrimidine compounds, process for producing them, their use and pharmaceutical compositions containing them
PL370554A1 (en) New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
IL165012A0 (en) (S)-4-Amino-5-chloro-2-methoxy-N-Ä1-(-tetrahydrofurylcarbonyl)-4-piperidinylmethylÜ-4-piperidinylÜbenzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
HUP0400040A2 (hu) Szulfonamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
IL161428A0 (en) Oligoamine derivatives, methods for the production thereof and pharmaceutical compositions containing the same
HUP0500137A2 (en) Pyrrolidine-2-ones as factor xa inhibitors, process for producing them and pharmaceutical compositions containing the same
HUP0100489A3 (en) New piperidine-4-sulphonamide compounds, process for their preparation and pharmaceutical compositions containing them
HUP0401082A3 (en) Substituted 4-aminocyclohexanols, process for their preparation and pharmaceutical compositions containing them
HUP0302429A3 (en) 4-amino-quinazolines, process for producing them, pharmaceutical compositions containing them and their use
AU2003231920A8 (en) Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them
HUP0301254A3 (en) Novel compounds, process fo their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees